Cancer 7: angiogenesis Flashcards

1
Q

What is angiogenesis?

A

the formation of a new blood vessel from pre-existing blood vessels

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What are the three ways of making blood vessels?

A
  • vasculogenesis
  • angiogenesis
  • arteriogenesis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What are the basic steps of sprouting?

A
  • growth factors are released that activate the endothelium cells to undergo a conformational change and send out filopodia in the direction of these factors
  • the end of the tip cell is modified to do this and they keep on moving until they interact with another tip cell, they fuse and stabilise
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What is the main trigger for angiogenesis?

A

hypoxia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

How does angiogenesis by hypoxia work?

A

there is a transcription factor called HIF that is normally inhibited by Von Hippel Lindau
-in hypoxia Von Hippel Lindel does not bind to HIF, so it can translocate to the nucleus and drive the expression of genes involved with angiogenesis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What are vascular endothelial growth factors?

A

-a family of 5 members: VEGF-A, VEGF-B, VEGF-C, VEGF-D and placental growth factor

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What are the three tyrosine kinase receptors?

A

VEGFR-1,2 and 3 and co receptors neuropilin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Which receptor is key in angiogenesis?

A

VEGFR-2

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What is the role of tip cells in sprouting angiogenesis?

A

they lead the growth of blood vessel cells towards gradients of VEGF
- a pathway called notch is crucial for the selection for tip cell

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What is the canonical notch signalling pathway?

A
  • the notch ligand binds to the notch receptor, activating it by cleaving the intracellular domain (NICD)
  • this then translocates to the nucleus and binds to transcription factor RBP-J
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Chemically how are notch cells selected for?

A
  • in stable blood vessels, DII4 and notch signalling remain minimal
  • VEGF activation increases the expression of DII4
  • DII4 drives notch signalling which inhibits the expression of VEGFR2 in the adjacent cell
  • the cells either side recognise their role as stalk cells and divide to push the tip cell forward
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What happens once the tip cell and sprout cells have been identified?

A
  • the cell needs to progress forward through the ECM
  • macrophages also have an important role as they have been shown to carve out tunnels in the ECM, guiding growth
  • proliferating stalk cells attract pericytes and deposit basement membranes to become stabilized
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What needs to happen after tip cells have fused?

A
  • the stalk cells separate to form a patent tube and now needs to STABILISE
  • this involves reforming the endothelial monolayer barrier and recruiting pericytes
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What is the role of cadherin in endothelial cells?

A
  • lines the junctions of endothelial cells
  • important in contact inhibition of cell growth
  • promote survival of endothelial cells
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

what is the role of VE-cadherin?

A

essential for vessel stabilisation and quiescence

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

what are the roles of pericytes?

A

important in the stabilisation of new blood vessels e.g. produce proteins like Angiopoietin 1

17
Q

What are mural cells?

A

smooth muscle cells AND pericytes

18
Q

What is the angiopoietin-Tie2 ligand receptor system?

A

-when ang-1 binds to Tie2 this promotes vessels stability and inhibits inflammatory gene expression
PROMOTES QUIESCENCE
-Ang2 promotes vascular instability and VEGF dependant angiogenesis

19
Q

How do tumours get their blood supply?

A
  • tumours less than 1 mm3 receive oxygen and nutrients by diffusion
  • larger tumours require a new vessel network- this stimulates migration, proliferation and neovessel formation by endothelial cells in adjacent established vessels
20
Q

What is the angiogenic switch?

A

the point at which a tumour reaches a certain size where diffusion is no longer sufficient, some of the cells become hypoxic and send angiogenic signals

21
Q

What are the characteristics of tumour blood vessels? (5)

A
  • irregularly shaped, dilated, tortuous
  • not organised into definitive venules, arterioles and capillaries
  • leaky and haemorrhagic, partly due to the overproduction of VEGF
  • perivascular cells often become loosely associated
  • some tumours may recruit endothelial progenitor cells from the bone marrow
22
Q

Which cells promote tumour angiogenesis?

A
  • fibroblasts
  • pericytes
  • platelets
23
Q

How do platelets lead to tumour angiogenesis?

A

activated platelets are a source of:

  • proangiogenic factors: VEGFA, PDGFs, FGF2
  • angiostatic molecules: thrombospondin 1, PAL1 and endostatin
24
Q

What are the side effects of avastin?

A
  • GI perforation
  • Hypertension
  • Proteinuria
  • Venous thrombosis
  • Haemorrage
  • Wound healing complications
25
Q

Why does avastin have limited efficiency?

A
  • VEGF inhibition aggravates hypoxia and so increasing the tumours release of other angiogenic factors
  • tumour vessels may be less sensitive to VEGF inhibition due to vessel lining
  • tumour cells that recruit pericytes maybe less responsive to VEGF therapy
26
Q

What is the anti-angiogenic therapy strategy?

A

to normalise vasculature

  • reduce hypoxia
  • increase efficacy of conventional therapies
27
Q

What is lucentis?

A

a modified version of Avastin used to treat age macular degeneration